[go: up one dir, main page]

MX2010001733A - Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis. - Google Patents

Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.

Info

Publication number
MX2010001733A
MX2010001733A MX2010001733A MX2010001733A MX2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A
Authority
MX
Mexico
Prior art keywords
compounds
imidazopyrazine compounds
formula
imidazopyrazine
cvb
Prior art date
Application number
MX2010001733A
Other languages
English (en)
Inventor
Clifford John Harris
Dale Robert Mitchell
Angus Macleod
Nicholas John Palmer
Michael Daniel Goldsmith
Christophe Claude Parsy
Original Assignee
Biofocus Dpi Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofocus Dpi Ltd filed Critical Biofocus Dpi Ltd
Publication of MX2010001733A publication Critical patent/MX2010001733A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de imidazopirazina que tienen una fórmula representada por la siguiente fórmula (l) Los compuestos pueden ser preparados como composiciones farmacéuticas, y pueden ser utilizados para la prevención y el tratamiento de una infección viral, en particular una infección por VHC, HRV, Sb, y/o CVB en un paciente que tenga la necesidad del mismo.
MX2010001733A 2007-08-21 2008-08-20 Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis. MX2010001733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0716292.8A GB0716292D0 (en) 2007-08-21 2007-08-21 Imidazopyrazine compounds
PCT/EP2008/060896 WO2009024585A2 (en) 2007-08-21 2008-08-20 Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis

Publications (1)

Publication Number Publication Date
MX2010001733A true MX2010001733A (es) 2010-07-06

Family

ID=38566736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001733A MX2010001733A (es) 2007-08-21 2008-08-20 Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.

Country Status (20)

Country Link
US (1) US8362018B2 (es)
EP (2) EP2193131B1 (es)
JP (1) JP2010536825A (es)
KR (1) KR20100081294A (es)
CN (1) CN101835780B (es)
AU (1) AU2008290531A1 (es)
BR (1) BRPI0815717A2 (es)
CA (1) CA2707521A1 (es)
CY (1) CY1113872T1 (es)
DK (1) DK2193131T3 (es)
ES (1) ES2404415T3 (es)
GB (1) GB0716292D0 (es)
HR (1) HRP20130202T1 (es)
MX (1) MX2010001733A (es)
NZ (1) NZ584108A (es)
PL (1) PL2193131T3 (es)
PT (1) PT2193131E (es)
SI (1) SI2193131T1 (es)
WO (1) WO2009024585A2 (es)
ZA (1) ZA201002009B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
MX2011002951A (es) 2008-09-26 2011-04-26 Boehringer Ingelheim Int Compuestos de azaindazol como antagonistas del receptor de ccr1.
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
SI2491028T1 (sl) 2009-10-21 2014-03-31 Boehringer Ingelheim International Gmbh Indazolne in pirazolopiridinske spojine kot antagonisti receptorja CCR1
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
AU2010311511B2 (en) 2009-10-30 2014-07-17 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
BR112012013582A2 (pt) * 2009-12-08 2016-07-05 Boehringer Ingelheim Int processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US9468642B2 (en) 2010-03-18 2016-10-18 Bayer Intellectual Property Gmbh Imidazopyrazines
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
ES2555261T3 (es) 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
CN103429592A (zh) * 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪
JP5822944B2 (ja) * 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
EP2651948A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
CN103403006B (zh) * 2010-12-17 2015-11-25 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪
CA2821817A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080230A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists
GB201109763D0 (en) * 2011-06-10 2011-07-27 Ucl Business Plc Compounds
CN103619846B (zh) 2011-06-27 2016-08-17 詹森药业有限公司 1-芳基-4-甲基-[1,2,4]三唑[4,3-a]喹喔啉衍生物
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
EP3288945B1 (en) * 2015-04-29 2019-09-18 Janssen Pharmaceutica NV Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
DK3288940T5 (da) 2015-04-29 2021-09-20 Janssen Pharmaceutica Nv Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer
JP6689299B2 (ja) * 2015-06-24 2020-04-28 キュロヴィル・アクチボラグ 療法に有用なピラゾロ［１，５−ａ］トリアジン−４−アミン誘導体
JP6507976B2 (ja) * 2015-09-30 2019-05-08 東レ株式会社 イミダゾール−２−カルボン酸エステル誘導体又はその塩の製造方法
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
SI3436074T1 (sl) * 2016-03-31 2020-09-30 Romark Laboratories, L.C. Tiazolidne spojine za zdravljenje virusnih infekcij
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
TW201817714A (zh) 2016-08-30 2018-05-16 英商葛蘭素史密斯克藍智慧財產權有限公司 抑制3c及3cl蛋白酶之化合物及其使用方法
SG11202003428VA (en) 2017-10-18 2020-05-28 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
BR112020014431A2 (pt) 2018-01-17 2020-12-01 Glaxosmithkline Intellectual Property Development Limited inibidores de pl4kiiibeta
BR112021002515A2 (pt) 2018-08-21 2021-07-27 Kyorin Pharmaceutical Co., Ltd. derivado de anel heteroaromático bicíclico
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN109369545B (zh) * 2018-12-14 2020-04-10 东营曜康医药科技有限公司 2-甲基-5-甲酸吡嗪的合成工艺
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
EP4157846A1 (en) * 2020-06-01 2023-04-05 F. Hoffmann-La Roche AG Novel imidazopyrazne derivatives
EP4161930A1 (en) * 2020-06-08 2023-04-12 F. Hoffmann-La Roche AG Novel imidazo-pyrazine derivatives
CN113929633A (zh) * 2021-10-27 2022-01-14 山东大学 一种法匹拉韦的合成方法及其应用
CN113831255B (zh) * 2021-11-25 2022-03-11 山东诚创蓝海医药科技有限公司 一种2-氨基丙二酰胺的制备方法
CN115489188B (zh) * 2022-10-09 2023-08-29 安徽国风新材料股份有限公司 一种家居保护用聚酯薄膜及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607813B1 (fr) * 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
DE19915178A1 (de) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
CA2409873C (en) 2000-05-23 2013-01-08 Washington University Hcv variants
AU2002225895A1 (en) 2000-11-07 2002-05-21 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
ES2287074T3 (es) 2000-12-22 2007-12-16 Boehringer Ingelheim (Canada) Ltd. Molecula de rna autorreplicante del virus de la hepatitis c.
EP2050822B1 (en) 2001-01-23 2013-07-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis C virus replicons and replicon enhanced cells
EP1363702A4 (en) * 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
MY134589A (en) * 2002-09-23 2007-12-31 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
AU2007200401A1 (en) * 2002-09-23 2007-02-22 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
ATE452192T1 (de) 2003-02-13 2010-01-15 Merck & Co Inc Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate
AR043002A1 (es) 2003-02-18 2005-07-13 Altana Pharma Ag Imidazopirazinas 6-substituidos
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2007058942A2 (en) 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
CA2628534A1 (en) 2005-11-10 2007-05-18 Schering Corporation Methods for inhibiting protein kinases
WO2008030795A2 (en) 2006-09-05 2008-03-13 Boards Of Regents, The University Of Texas System Compositions and methods for inhibition of tyrosine kinases
AU2007338601C1 (en) 2006-09-05 2014-07-24 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection
CN101589045A (zh) 2006-11-08 2009-11-25 先灵公司 作为蛋白质激酶抑制剂的咪唑并吡嗪
WO2008059373A1 (es) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Vacuna contra la malaria, basada en la subunidad 200l de la proteína msp1 de plasmodium vivax.
US8243049B2 (en) 2006-12-20 2012-08-14 3M Innovative Properties Company Untethered stylus employing low current power converter
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds

Also Published As

Publication number Publication date
WO2009024585A2 (en) 2009-02-26
HK1143810A1 (en) 2011-01-14
EP2193131B1 (en) 2013-01-30
CN101835780B (zh) 2013-09-18
EP2567960A2 (en) 2013-03-13
ZA201002009B (en) 2010-12-29
KR20100081294A (ko) 2010-07-14
DK2193131T3 (da) 2013-04-22
GB0716292D0 (en) 2007-09-26
CN101835780A (zh) 2010-09-15
NZ584108A (en) 2012-06-29
AU2008290531A1 (en) 2009-02-26
US8362018B2 (en) 2013-01-29
EP2193131A2 (en) 2010-06-09
SI2193131T1 (sl) 2013-06-28
PT2193131E (pt) 2013-04-04
PL2193131T3 (pl) 2013-07-31
BRPI0815717A2 (pt) 2015-02-10
US20110166147A1 (en) 2011-07-07
CA2707521A1 (en) 2009-02-26
ES2404415T3 (es) 2013-05-27
EP2567960A3 (en) 2013-06-05
HRP20130202T1 (hr) 2013-04-30
CY1113872T1 (el) 2016-07-27
JP2010536825A (ja) 2010-12-02
WO2009024585A3 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
TN2012000416A1 (en) Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2008127364A3 (en) Antiviral compounds and use thereof
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
SG178952A1 (en) Chemical compounds
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
ZA201002690B (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
WO2010084115A3 (en) Antiviral agents
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
ZA200900935B (en) Hepatitis C virus inhibitors
WO2008021936A3 (en) Hepatitis c virus inhibitors
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
PH12012501216A1 (en) Hcv combination therapy
WO2007041632A3 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
MX2011011618A (es) Agentes terapeuticos 713.

Legal Events

Date Code Title Description
FG Grant or registration